Press Releases

Date Title and Summary Additional Formats
Toggle Summary Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing
DURHAM, N.C., June 16, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today
View HTML
Toggle Summary Argos Provides Update on its ADAPT Trial Following Meeting with FDA
DURHAM, N.C., May 10, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® precision immunotherapy technology platform, today provided an update on the
View HTML
Toggle Summary Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial
DURHAM, N.C., April 18, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® precision immunotherapy technology platform, today reported interim results
View HTML
Toggle Summary Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review
-Company to host conference call today, February 22, 2017 at 8:30am EST- DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ®
View HTML
Toggle Summary Argos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium
Company to present a poster on the development of immunotherapy for muscle invasive bladder cancer
View HTML
Toggle Summary Argos Therapeutics to Participate in BIO CEO and Investor Conference
DURHAM, N.C., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the
View HTML
Toggle Summary Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University
40,000 square feet of newly constructed space at the Center for Technology & Innovation to support initial commercialization of company's individualized immunotherapies
View HTML
Toggle Summary Argos Therapeutics Enters into Strategic Research Agreement with Personalis, Inc.
-Personalis to support ongoing research efforts to demonstrate that Argos' lead product candidate, rocapuldencel-T, specifically targets patients' tumor-specific neoantigens without the need to identify them first-
View HTML
Toggle Summary Argos Therapeutics Appoints Dr. Ralph Snyderman and Irackly Mtibelishvily to the Company's Board of Directors
- Dr. Snyderman widely considered the ‘Father of Personalized Medicine' -
View HTML
Toggle Summary Argos Therapeutics Reports Highlights from Investor Day in New York City
Company announces planning for implementation of two-stage manufacturing strategy and rocapuldencel-T as generic name for lead product candidate for treatment of metastatic renal cell carcinoma
View HTML

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Tweets